TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7856286

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril 3 x 12.5 mg, lisinopril 1 x 10 mg, enalapril 1 x 10 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril, lisinopril, enalapril)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ACE inhibitors with acetylsalicylic acid
Number of subjects: 31
Study: 2530717

Group type: EXPERIMENTAL
Intervention: 1‐Ar (1-inch needle injection in the arm)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1‐Bu (1-inch needle injection in the buttock)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 2‐Bu (2-inch needle injection in the buttock)
Number of subjects: 3
Study: 588914

Group type: EXPERIMENTAL
Intervention: Computerized tomography (CT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 50
Study: 30211826

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 83

Group type: COMPARATOR
Intervention: CNI-based treatment
Number of subjects: 83
Study: 28732433

Group type: EXPERIMENTAL
Intervention: Salt therapy (staying in the salt room for one hour, three times a week for 3 consecutive weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (three weeks under observation)
Number of subjects: 34
Study: 25803604

Group type: EXPERIMENTAL
Intervention: Tai Chi plus behavioral weight loss program (TCWL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 29
Study: 23535113

Group type: EXPERIMENTAL
Intervention: External ventricular drainage (EVD) from ipsilateral ventricle (IG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: External ventricular drainage (EVD) from contralateral ventricle (CG)
Number of subjects: 45
Study: 21482569

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 0
Study: 19931751

Group type: EXPERIMENTAL
Intervention: Calculated weight estimates using midarm circumference and knee height measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician estimates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse estimates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient self-reported estimates
Number of subjects: 0
Study: 17467230

Group type: EXPERIMENTAL
Intervention: Psychological intervention (weekly for 4 months, followed by monthly sessions for 8 months)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 227
Study: 15733403

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (8‐70 mA, 20 min, qd, for 20‐30 times)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral tolterodine 2 mg, bid, for 2‐4 weeks
Number of subjects: 60
Study: 11738122

Group type: EXPERIMENTAL
Intervention: Antihypertensive and lipid-lowering therapy
Number of subjects: 42419
Study: 9624745

Group type: EXPERIMENTAL
Intervention: Counselling service
Number of subjects: 385
Study: 8147352

Group type: EXPERIMENTAL
Intervention: Antimycobacterial drugs (ethambutol, clofazimine, dapsone, and 1-day dose of rifampicin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3347325

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 101

Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide (HCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: HCT dosage doubled after 1 month
Number of subjects: 101
Study: 31133624

Group type: EXPERIMENTAL
Intervention: High-intensive intervention group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Low-intensive intervention group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 27768509

Group type: EXPERIMENTAL
Intervention: Follow-up care (valued by participants)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Monthly payment willingness to pay (WTP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: One-time payment willingness to pay (WTP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Factors predicting higher WTP
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Annual cancer-related visits
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Agreement to pay for follow-up care
Number of subjects: 32
Study: 25812483

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (weekly or bi-weekly assessments via texts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (routine and urgent follow-up visits and telephone calls)
Number of subjects: 0
Study: 23672202

Group type: EXPERIMENTAL
Intervention: Irsogladine 4 mg daily for 14 days with diclofenac sodium 75 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Omeprazole 10 mg daily for 14 days with diclofenac sodium 75 mg
Number of subjects: 32
Study: 21799130

Group type: EXPERIMENTAL
Intervention: High-velocity PRT (3.5 times higher velocity against reduced loads)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low-velocity PRT (shortening contractions at low velocities against high loads)
Number of subjects: 63
Study: 18957313

Group type: EXPERIMENTAL
Intervention: Patients with OCD
Number of subjects: 28
Study: 17420341

Group type: EXPERIMENTAL
Intervention: Same-day discharge
Number of subjects: 800

Group type: COMPARATOR
Intervention: Overnight stay
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Same-day discharge (suitable for early discharge)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Overnight stay (suitable for early discharge)
Number of subjects: 800
Study: 15564693

Group type: EXPERIMENTAL
Intervention: Facilitated percutaneous coronary intervention (PCI)
Number of subjects: 168
Study: 11429342

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.04 microg.kg(‐1).h(‐1) (Group RC1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.08 microg.kg(‐1).h(‐1) (Group RC2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.12 microg.kg(‐1).h(‐1) (Group RC3)
Number of subjects: 55

Group type: COMPARATOR
Intervention: ropivacaine 0.1% 0.2 mg.kg(‐1).h(‐1) (Group R)
Number of subjects: 55
Study: 9589248

Group type: EXPERIMENTAL
Intervention: Becaplermin gel 100 micrograms/g
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 382
Study: 7750174

Group type: EXPERIMENTAL
Intervention: Temporal point acupuncture (TG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Body acupuncture (BG)
Number of subjects: 108
Study: 2532741

Group type: EXPERIMENTAL
Intervention: Intravenous 99‐126 atrial natriuretic factor (ANF) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 5451146

Group type: EXPERIMENTAL
Intervention: Penicillin‐chloramphenicol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalothin‐kanamycin
Number of subjects: 0
Study: 30945431

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (TOFO)
Number of subjects: 775
Study: 29574980

Group type: EXPERIMENTAL
Intervention: Ramipril (an angiotensin-converting enzyme inhibitor)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26657621

Group type: EXPERIMENTAL
Intervention: Integrated community health promotion platform
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 22628143

Group type: EXPERIMENTAL
Intervention: Video games (three commercially available games)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous Performance Test II (CPT II)
Number of subjects: 42
Study: 23113480

Group type: EXPERIMENTAL
Intervention: 0.5% ivermectin lotion
Number of subjects: 765

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 765
Study: 20434097

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 15 mg of hyperbaric ropivacaine plus 25 microg of fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose spinal anesthesia with 10 mg of hyperbaric ropivacaine plus 25 microg of fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 112.5 mg of ropivacaine plus 25 microg of fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 16680447

Group type: EXPERIMENTAL
Intervention: Recurrent low back pain cases (female workers with LBP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healthy controls (female workers without LBP)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: PPT on the forehead
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: PPT on the lower back
Number of subjects: 106
Study: 16259851

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic intervention (BDI)
Number of subjects: 70
Study: 11867660

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 439

Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 439
Study: 10188723

Group type: EXPERIMENTAL
Intervention: Degenerate PCR approach for HPV-DNA detection
Number of subjects: 117
Study: 7489665

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPHA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2318518

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg once or twice daily or 50 mg once or twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydralazine, methyldopa, metoprolol, or reserpine (added to diuretic therapy for nonresponders)
Number of subjects: 0
Study: 6931717

Group type: EXPERIMENTAL
Intervention: Vestibular and lingual osteotomy
Number of subjects: 50
Study: 29474306

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab combined with oral DHA supplementation (1,050 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab alone (control group)
Number of subjects: 55
Study: 28285845

Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg once daily for 14-18 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 26096474

Group type: EXPERIMENTAL
Intervention: Booster massage (60 minutes 1x/wk)
Number of subjects: 179

Group type: COMPARATOR
Intervention: No additional massage
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: 60-minute massage groups
Number of subjects: 179
Study: 22859317

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) protocol: systemic NAC infusion (30 mg/kg) 1 hour before liver procurement and locoregional NAC infusion (300 mg through the portal vein) just before cross-clamping
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (standard protocol without NAC)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) protocol
Number of subjects: 140
Study: 20093971

Group type: EXPERIMENTAL
Intervention: Periodized resistance training (PRT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 45
Study: 19696213

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study: 17707639

Group type: EXPERIMENTAL
Intervention: Surgery +/‐ radiotherapy for localized unresectable disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy +/‐ radiotherapy followed by delayed surgical resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with surgical resection for metastatic disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of ifosfamide and doxorubicin in chemotherapy regimes
Number of subjects: 0
Study: 15236398

Group type: EXPERIMENTAL
Intervention: Levodopa (100mg daily for 5 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11878738

Group type: EXPERIMENTAL
Intervention: Epidural methylprednisolone (MP) 1 mg kg(‐1) followed by continuous infusion of MP 1.5 mg kg(‐1) for 48 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.9% saline as a bolus injection and continuous epidural infusion (P group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural methylprednisolone (MP)
Number of subjects: 24
Study: 9781732

Group type: EXPERIMENTAL
Intervention: Helium-oxygen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Air-oxygen
Number of subjects: 18
Study: 7819468

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) administered to reduce mean arterial pressure to 50 mmHg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no SNP)
Number of subjects: 30
Study: 3306374

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (30 mg/kg)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 382
Study: 28922734

Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.2mg/kg ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 24
Study: 26872958

Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavioral Treatment (ABBT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional Cognitive-Behavioral Treatment (tCBT)
Number of subjects: 21
Study: 24305788

Group type: EXPERIMENTAL
Intervention: Pre-operative autologous blood donation (PABD) - 1 dose 72 hours prior to TKA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-operative autologous blood donation (PABD) - 14 days prior to TKA
Number of subjects: 0

Group type: COMPARATOR
Intervention: No autologous blood donation
Number of subjects: 0
Study: 23774876

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted elvitegravir (EVG/r; 50/100 mg QD) administered alone or with antacid simultaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cobicistat-boosted elvitegravir (EVG/co; 150/150 mg QD) administered simultaneously or staggered (+12 hours) with famotidine or omeprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staggered antacid administration by ≥2 hours
Number of subjects: 0
Study: 15752122

Group type: EXPERIMENTAL
Intervention: PUVA-gel therapy (aqueous 8-methoxypsoralen (8-MOP)-containing gel plus broadband UVA irradiation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PUVA-bath therapy (8-MOP bath of the hands and/or feet plus broadband UVA)
Number of subjects: 20
Study: 11812684

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA) with ropivacaine 1% (4‐mL bolus, 3‐5 mL/h infusion), fentanyl (100‐microg bolus, 15‐25 microg/h infusion), and propofol infusion (6 mg x kg(‐1) x h(‐1))
Number of subjects: 100

Group type: COMPARATOR
Intervention: General Anesthesia with fentanyl (15 microg/kg) and propofol (5 mg x kg(‐1) x h(‐1)), followed by IV morphine patient‐controlled analgesia
Number of subjects: 100
Study: 10690138

Group type: EXPERIMENTAL
Intervention: 0.25% S(‐)‐bupivacaine
Number of subjects: 137

Group type: COMPARATOR
Intervention: 0.25% RS‐bupivacaine
Number of subjects: 137
Study: 7732155

Group type: EXPERIMENTAL
Intervention: Social support from partner
Number of subjects: 66

Group type: COMPARATOR
Intervention: Social support from stranger
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Social support from boyfriend/girlfriend
Number of subjects: 66

Group type: COMPARATOR
Intervention: No social support
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overall subjective well-being in partner support condition
Number of subjects: 66

Group type: COMPARATOR
Intervention: Stranger support
Number of subjects: 66
Study: 1836919

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV
Number of subjects: 111

Group type: COMPARATOR
Intervention: DT and OPV alone (control group)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Group III)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Groups I and II)
Number of subjects: 111
Study: 7222859

Group type: EXPERIMENTAL
Intervention: Intravenous tinofedrine (0.12 to 0.17 mg/kg body‐weight)
Number of subjects: 23
Study: 30098134

Group type: EXPERIMENTAL
Intervention: Insulin-stimulated brain glucose uptake (BGU) in obese participants
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Insulin-stimulated brain glucose uptake (BGU) in obese participants post-bariatric surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High insulin-stimulated BGU at baseline
Number of subjects: 32

Group type: COMPARATOR
Intervention: Insulin-stimulated brain glucose uptake (BGU) in all participants
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weight loss in obese participants post-bariatric surgery
Number of subjects: 32
Study: 28089575

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Gonadotropins
Number of subjects: 900

Group type: COMPARATOR
Intervention: Participants with fibroids
Number of subjects: 900

Group type: COMPARATOR
Intervention: African American women with fibroids
Number of subjects: 900
Study: 25762357

Group type: EXPERIMENTAL
Intervention: OFD + PRF
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: OFD + 1% MF
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: OFD + PRF + 1% MF
Number of subjects: 120

Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 120
Study: 23751236

Group type: EXPERIMENTAL
Intervention: 1000mcg chromium/day (high dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600mcg chromium/day (moderate dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21523925

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (MLD) once a week for 5 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Observation group (control)
Number of subjects: 35
Study: 19090875

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (3 doses)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 16531393

Group type: EXPERIMENTAL
Intervention: 4-Hz metronome
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-Hz metronome
Number of subjects: 0
Study: 12769159

Group type: EXPERIMENTAL
Intervention: HDk lenses
Number of subjects: 134

Group type: COMPARATOR
Intervention: LDk lenses
Number of subjects: 134
Study: 10669265

Group type: EXPERIMENTAL
Intervention: PaO2 during anaesthesia with F(I)O2=0.33
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Smoking more than 20 pack-years
Number of subjects: 40
Study: 9062374

Group type: EXPERIMENTAL
Intervention: Antidepressants (sertraline and imipramine)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 410

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 410
Study: 8376215

Group type: EXPERIMENTAL
Intervention: Contralateral sound stimulation (NBN frequencies centered between 0.25 and 8 kHz)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Contralateral sound stimulation (NBN frequencies centered around 1 kHz)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Contralateral sound stimulation (NBN frequencies around 2 kHz and lower frequencies around 1 kHz)
Number of subjects: 39
Study: 3085552

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms/kg (group 1, n = 6)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fentanyl 8 micrograms/kg (group 2, n = 20)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms/kg plus continuous intravenous nitroglycerin infusion 0.9 microgram X kg‐1 X min‐1 (group 3, n = 20)
Number of subjects: 46
Study: 30182786

Group type: EXPERIMENTAL
Intervention: JNJ-42847922 (5-60 mg orally once daily for 10 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: JNJ-42847922 (doses >5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: JNJ-42847922 (doses >10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 27154159

Group type: COMPARATOR
Intervention: 5 mg/kg intravenous methylprednisolone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone
Number of subjects: 30
Study: 24943472

Group type: EXPERIMENTAL
Intervention: Sport-for-development programme (11-week voluntary competitive football league)
Number of subjects: 1462
Study: 22864179

Group type: EXPERIMENTAL
Intervention: Omeprazole 10mg daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Famotidine 20mg daily
Number of subjects: 130
Study: 21260940

Group type: EXPERIMENTAL
Intervention: High-frequency intravesical electroneurostimulation with magnetophoresis of oxibutinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral intake of oxibutinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (intravesical electroneurostimulation and magnetophoresis)
Number of subjects: 0
Study: 18832294

Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg 3 times daily after 7 days of ambrisentan 10 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: N-desmethyl sildenafil
Number of subjects: 19
Study: 15963399

Group type: EXPERIMENTAL
Intervention: High-dose furosemide (500 to 1,000 mg) plus hypertonic saline solution (HSS) twice a day for four to six days
Number of subjects: 94

Group type: COMPARATOR
Intervention: High-dose furosemide (500 to 1,000 mg) alone, twice a day for four to six days
Number of subjects: 94
Study: 12835083

Group type: EXPERIMENTAL
Intervention: Neoral (Group I)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FK506 (Group II)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 10829126

Group type: EXPERIMENTAL
Intervention: Emotional slide exposure with self-relevant instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Original design of Christianson and E.F. Loftus (1991)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic variation of stimulus exposure and interstimulus interval durations
Number of subjects: 0
Study: 8723803

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Intervention (KMI) including kangaroo position, kangaroo nutrition, and kangaroo discharge policies
Number of subjects: 0
Study: 1947785

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 6223430

Group type: EXPERIMENTAL
Intervention: Spectinomycin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 32